Ambulatory Pain Ambulatory Pain Management Management Richard T. Jermyn D.O., Richard T. Jermyn D.O., F.A.A.P.M.R. F.A.A.P.M.R. Associate Professor: Associate Professor: UMDNJ:SOM UMDNJ:SOM Acting Chair: Department of Acting Chair: Department of PM&R PM&R Director: NMI Director: NMI
48
Embed
Ambulatory Pain Management Richard T. Jermyn D.O., F.A.A.P.M.R. Associate Professor: UMDNJ:SOM Acting Chair: Department of PM&R Director: NMI.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Richard T. Jermyn D.O., F.A.A.P.M.R.Richard T. Jermyn D.O., F.A.A.P.M.R.Associate Professor: UMDNJ:SOMAssociate Professor: UMDNJ:SOMActing Chair: Department of PM&RActing Chair: Department of PM&RDirector: NMIDirector: NMI
DisclosureDisclosureRichard Jermyn, DORichard Jermyn, DO
CompanyCompany
Consultant and Consultant and Speaker’s BureauSpeaker’s Bureau
Endo Pharmaceuticals, Endo Pharmaceuticals, Alpharma Inc., and Pfizer Inc.Alpharma Inc., and Pfizer Inc.
Grant ResearchGrant Research Endo PharmaceuticalsEndo Pharmaceuticals
ObjectivesObjectives
Learn how to interview a pain patientLearn how to interview a pain patient Review pharmacology of pain medicationsReview pharmacology of pain medications Common treatments for the pain patientCommon treatments for the pain patient Understand the pathophysiology of painUnderstand the pathophysiology of pain
CASE STUDYCASE STUDY
Patient is a 53 year old female with a 10 year history of Patient is a 53 year old female with a 10 year history of Diabetes Mellitus. Patient has severe pain in feet and Diabetes Mellitus. Patient has severe pain in feet and legs VAS 9 (1-10) for 1 year. Patient admits to not using legs VAS 9 (1-10) for 1 year. Patient admits to not using her insulin and blood sugars are usually above 200. her insulin and blood sugars are usually above 200. You have no medical records.You have no medical records.
Diagnosed with osteoarthitis of both kneesDiagnosed with osteoarthitis of both knees History of Lumbar spinal stenosis History of Lumbar spinal stenosis
Case StudyCase Study
Works as a waitress but strugglesWorks as a waitress but struggles Limited incomeLimited income
Case StudyCase Study
Patient taking Neurontin 600mg Patient taking Neurontin 600mg (Gabapentin) TID (Gabapentin) TID
Lymes, toxoplasmosis, HIVLymes, toxoplasmosis, HIV– Treatments that have failedTreatments that have failed
Pain AssessmentPain Assessment
Social History:Social History:– Live alone or partneredLive alone or partnered– Single or multiple story homesSingle or multiple story homes– Assistive devicesAssistive devices– FallsFalls– DriveDrive– HobbiesHobbies
Goals for treatment: work, childcare, school, Goals for treatment: work, childcare, school, sportssports
Physical ExamPhysical Exam
Upper motor neuron vs. lower motor neuronUpper motor neuron vs. lower motor neuron
Physical ExamPhysical Exam
Upper motor neuron:Upper motor neuron:– hyper-reflexiahyper-reflexia– spasticityspasticity– hoffmans/babinskihoffmans/babinski– frontal release signsfrontal release signs– ataxia, tremor, dysmetriaataxia, tremor, dysmetria
Physical ExamPhysical Exam
Lower Motor NeuronLower Motor Neuron– decreased reflexesdecreased reflexes– weaknessweakness
Upper Motor NeuronUpper Motor Neuron
Metabolic: common drug effectsMetabolic: common drug effects Lymphoma: CNS tumorsLymphoma: CNS tumors Primary or metastatic cancerPrimary or metastatic cancer CVA: thalamic syndrome, hand-shoulder CVA: thalamic syndrome, hand-shoulder
– Drug effectsDrug effects Arthropathies: OAArthropathies: OA Autoimmune: RAAutoimmune: RA Infectious Disease: Herpes zosterInfectious Disease: Herpes zoster
Normal Pain Pathways
Adapted with permission, from Fields. In: Adapted with permission, from Fields. In: The Placebo Effect: AnThe Placebo Effect: An Interdisciplinary ExInterdisciplinary Expplorationloration. 1997.. 1997.
Agonist and Agonist-antagonistsAgonist and Agonist-antagonists– bind to opioid receptorsbind to opioid receptors
sustained released and short acting agentssustained released and short acting agents Oral route is most preferredOral route is most preferred mainstay for moderate to severe painmainstay for moderate to severe pain never dose as PRNnever dose as PRN
OpioidsOpioids
Start with the lowest possible dose possibleStart with the lowest possible dose possible titrate the drugtitrate the drug place the patient on a schedule and never place the patient on a schedule and never
PRNPRN use combinations of opioids and non-opioidsuse combinations of opioids and non-opioids be aware of tolerencebe aware of tolerence
OpioidsOpioids
Weaker Opioids analgesics:Weaker Opioids analgesics:– oxycodone, hydrocodone, codeineoxycodone, hydrocodone, codeine– available in combinations with ASA/aceto.available in combinations with ASA/aceto.
Long-acting agents for 24 hr. reliefLong-acting agents for 24 hr. relief
Short-acting agents for breakthru painShort-acting agents for breakthru pain– no more than 2 times daily (debated)no more than 2 times daily (debated)– Combo drugs; Percocet (Oxycodone HCI), Vicodin Combo drugs; Percocet (Oxycodone HCI), Vicodin
– Uncombinated drugs; Oxy IR (Oxycodone HCI), Actiq Uncombinated drugs; Oxy IR (Oxycodone HCI), Actiq (Fentanyl Citrate)(Fentanyl Citrate)
Treat side effects such as constipationTreat side effects such as constipation
MethadoneMethadone
Long half life: 24-150hrsLong half life: 24-150hrs Duration of activity: 4-6hrs.Duration of activity: 4-6hrs. Toxicity with overlapping half livesToxicity with overlapping half lives HIV meds can decrease the serum level of HIV meds can decrease the serum level of
When switching to methadone to another When switching to methadone to another analgesic: decrease 75-90% equi-analgesic analgesic: decrease 75-90% equi-analgesic dosedose
Take maintance Dose decrease 20% and Take maintance Dose decrease 20% and divide to tid-qid.divide to tid-qid.
Short acting for withdrawal symptomsShort acting for withdrawal symptoms
TransdermalTransdermal
98% protein bound98% protein bound– Must have protein to be absorbedMust have protein to be absorbed– Must have protein to be excretedMust have protein to be excreted
Absorption of the drug increased as the Absorption of the drug increased as the temperature increases.temperature increases.– 101-103 degrees101-103 degrees
Tramadol (Ultram)Tramadol (Ultram)
Centrally Acting Oral Opioid AgonistCentrally Acting Oral Opioid Agonist Serotonin and NoradrenerginSerotonin and Noradrenergin Dizziness, Nausea and HeadacheDizziness, Nausea and Headache
AntidepressantsAntidepressants
Works on serotonin and noradrenerginWorks on serotonin and noradrenergin tricyclics, hetero, SNRI, SSRItricyclics, hetero, SNRI, SSRI potentiate the opiatespotentiate the opiates treat depression as a side effecttreat depression as a side effect
Pain relief is related to serum level.Pain relief is related to serum level. Dose at night to allow improved sleepDose at night to allow improved sleep SSRI’s are believed to be not as beneficial SSRI’s are believed to be not as beneficial
in pain relief until recentlyin pain relief until recently Warn patients about side effectsWarn patients about side effects
AnticonvulsantsAnticonvulsants
Gabapentine (Neurontin):Gabapentine (Neurontin):– works on GABAworks on GABA– start at low doses and titrate upwardstart at low doses and titrate upward– check renal profiles: renal excretioncheck renal profiles: renal excretion– potentiate opioids weaklypotentiate opioids weakly– strong mood stabilizerstrong mood stabilizer
AnticonvulsantsAnticonvulsants
Valproic Acid: extreme caution in liver Valproic Acid: extreme caution in liver disease, monitor blood levels, neural tube disease, monitor blood levels, neural tube defects in fetus, dizziness, headache, defects in fetus, dizziness, headache, thrombocytopeniathrombocytopenia
Lyrica (Pregabalin): Schedule V, sedation, weight Lyrica (Pregabalin): Schedule V, sedation, weight gaingain– May be less sedating than Neurontin (Gabapentin)May be less sedating than Neurontin (Gabapentin)– Indicated for post-herpetic neuralgia, diabetic Indicated for post-herpetic neuralgia, diabetic
neuropathyneuropathy
AntispasmodicsAntispasmodics
Flexeril (Cyclobenzaprine): central acting, Flexeril (Cyclobenzaprine): central acting, unknown mechanism, anticholinergic side unknown mechanism, anticholinergic side effectseffects
baclofen: central acting, drowsiness, baclofen: central acting, drowsiness, confusion, seizures with abrupt withdrawalconfusion, seizures with abrupt withdrawal
parafon forte: central acting, GI upset, parafon forte: central acting, GI upset, drowsinessdrowsiness
Muscle RelaxantsMuscle Relaxants
Robaxane: central acting, drowsiness, Robaxane: central acting, drowsiness, dizziness, GI upset, blurred vision, dizziness, GI upset, blurred vision, headacheheadache
Skelaxin (Metaxalone): central acting Skelaxin (Metaxalone): central acting leukopenia, hemolytic anemia, dizziness leukopenia, hemolytic anemia, dizziness
Serotonin and noradrenergicSerotonin and noradrenergic potentiate opioidspotentiate opioids powerful mood stabilizerpowerful mood stabilizer improves appetite when wastingimproves appetite when wasting improves sedationimproves sedation dose in am and noon onlydose in am and noon only
Not as common in the elderlyNot as common in the elderly Place patient in a drug agreementPlace patient in a drug agreement
– monthly visitmonthly visit– one pharmacy onlyone pharmacy only– can not use, sell, trade drugscan not use, sell, trade drugs– take as specified - no renewalstake as specified - no renewals
Detox when appropriate - not when sickDetox when appropriate - not when sick Treat other symptoms: depressionTreat other symptoms: depression